Anticholinergic Burden in the Elderly: Assessment and Reduction Strategies

This post is for consultant pharmacists and clinical pharmacy directors who conduct medication regimen reviews (MRR) in skilled nursing / long-term care (SNF) and other settings serving older adults. You will get a practical framework for assessing anticholinergic burden in the elderly, deciding where to intervene, and documenting reductions that hold up to regulatory scrutiny.

Why anticholinergic burden matters in older adults

Anticholinergic medications block acetylcholine, and the cumulative effect of several such drugs — the anticholinergic burden (ACB) — rises quickly in complex regimens. Older adults are more vulnerable because of age-related changes in pharmacokinetics, pharmacodynamics, and blood-brain barrier permeability.

A high ACB is associated in the literature with cognitive impairment, delirium, falls, constipation, urinary retention, dry mouth, and blurred vision. For frail residents, these effects can compound and masquerade as decline, driving additional prescribing in a cascade the consultant pharmacist is positioned to interrupt.

The point of assessment is not to eliminate every anticholinergic drug. It is to make the burden visible, weigh it against the clinical indication, and document a defensible judgment for each agent.

How anticholinergic burden is scored

Several validated tools exist, and they do not always agree. Understanding what each one measures helps you choose a consistent approach across your facilities.

• Anticholinergic Cognitive Burden (ACB) Scale — assigns point values (commonly 1 to 3) based on the strength of a drug's anticholinergic activity, then sums across the regimen.
• Anticholinergic Drug Scale (ADS) — a graded scale weighting agents by potency.
• Anticholinergic Risk Scale (ARS) — a ranked list used to estimate the risk of adverse anticholinergic effects.

Because scales use different drug lists and weightings, a patient's total score can vary by instrument. Pick one scale as your standard, apply it consistently, and note which tool you used so your documentation is reproducible.

These tools complement, rather than replace, broader explicit criteria. The American Geriatrics Society (AGS) Beers Criteria flag certain anticholinergic medications as potentially inappropriate in older adults, and the STOPP/START criteria identify potentially inappropriate prescribing and prescribing omissions. Review the official AGS publications and criteria updates directly, since these sets are periodically revised.

Common contributors you will see in the chart

Anticholinergic activity shows up across many therapeutic classes, and some contributors are easy to overlook because their primary indication is not anticholinergic. Categories frequently implicated in the geriatric literature include:

• Sedating antihistamines used for sleep or allergy
• Certain tricyclic antidepressants and some other psychotropics
• Bladder antimuscarinics prescribed for overactive bladder
• Some antispasmodics, antiemetics, and muscle relaxants
• Selected agents for Parkinsonism and related symptoms

Always confirm a specific drug's scoring against your chosen scale and the current Beers and STOPP/START criteria rather than relying on memory. Formulations and newer agents may not carry the same burden as older members of a class.

A structured assessment workflow

During the MRR, a repeatable sequence keeps the review efficient and consistent across a census.

1. Inventory every agent with anticholinergic activity, including PRN and as-needed orders, topicals, and over-the-counter products documented in the record.
2. Calculate the cumulative score using your standardized scale, and note the total alongside the contributing drugs.
3. Correlate with the clinical picture — the consultant pharmacist evaluates whether symptoms such as confusion, falls, constipation, or urinary retention could plausibly relate to the burden, without asserting causation for any individual.
4. Weigh indication against risk for each contributor, considering whether the original indication still applies and whether a lower-burden alternative or non-drug approach may be appropriate.
5. Prioritize the highest-weight agents and those with the weakest ongoing indication for discussion with the prescriber.

Note that this is general professional education. Any decision to continue, substitute, or deprescribe a medication for a specific resident is a clinical judgment made by the licensed prescriber and pharmacist based on that individual's full picture.

Principles of anticholinergic reduction

Reduction is rarely about a single dramatic change. The literature and deprescribing frameworks emphasize a measured approach.

• Target the clearest wins first. Duplicative therapy, agents without a current indication, and high-potency contributors are logical starting points for prescriber discussion.
• Consider lower-burden alternatives. Where a therapeutic need remains, the team may evaluate whether an agent with less anticholinergic activity, or a non-pharmacologic option, could meet the goal.
• Taper where withdrawal effects are a concern, rather than stopping abruptly, consistent with recognized deprescribing guidance and the patient's circumstances.
• Monitor and reassess. Reduction is a hypothesis to be tested — track whether target symptoms improve and whether the underlying condition remains controlled.

Frame each recommendation around the clinical question, the relevant criteria, and the monitoring plan. That structure respects the prescriber's authority and produces a cleaner record.

Documentation that supports compliance

ACB reduction intersects with the broader push toward reducing unnecessary medications in long-term care. CMS requires that each resident's drug regimen be free of unnecessary medications and reviewed by a licensed pharmacist; the consultant's recommendations, the prescriber's response, and the rationale all belong in the record.

For the authoritative and current requirements, consult the CMS State Operations Manual and the official guidance at cms.gov, and verify the clinical criteria against the current AGS Beers and STOPP/START publications, because both the regulations and the criteria are updated over time.

Good documentation captures the scale used, the calculated burden, the contributing agents, the specific recommendation, and the monitoring plan — plus an auditable trail of who signed off and when. That record protects the resident, the prescriber, and the facility. You can see how this fits a full geriatric review workflow on the SNF solution page and across the platform overview.

Building ACB review into routine MRR

The most durable programs do not treat anticholinergic burden as a one-off project. They fold scoring into every scheduled review so that burden is recalculated as orders change, new admissions arrive, and acute events occur.

Consistency is what makes trends visible. When the same scale and the same documentation structure are applied census-wide, you can identify facility-level patterns, support quality improvement, and demonstrate a defensible, repeatable process to surveyors and medical directors.

How WeConsultRx helps

The WeConsultRx clinical engine brings 49 codified rules across Beers 2023, STOPP/START v2, and ACB into a single medication regimen review, surfacing anticholinergic contributors and potentially inappropriate agents so you spend your time on clinical judgment rather than manual cross-referencing. Each recommendation flows into consultant e-signature sign-off and an append-only audit trail, giving you documentation that is consistent, reproducible, and ready for survey. Request a demo to see how it fits your geriatric review workflow.

Frequently asked questions